Jason Ryan
CIK 1585017 · Executive Chairman · last filed 2026-06-23
Jason Ryan is an Executive Chairman who has filed 67 SEC Form 4 insider transactions across 7 companies since 2014. The most recent filing, for WGS, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$18.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $7.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$7.35M
7
67
-$18.54M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WGS | Director | 118,764 | $61.88 | $7.35M | $0 | 1 | 2026-06-23 |
| WGSWW | Director | 135,473 | $0.00 | $27 | -$8.15M | 11 | 2025-08-27 |
| Singular Genomics Systems, Inc. (OMIC) Delisted | Director | — | $20.01 | — | $0 | 3 | 2024-05-31 |
| SomaLogic, Inc. (SLGCW) Delisted | Director | — | $0.09 | — | $0 | 1 | 2023-06-12 |
| GeneDx Holdings Corp. (SMFRW) Delisted | Executive Chairman | 263,358 | $0.02 | $6.3K | -$20.4K | 6 | 2023-01-04 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | See Remarks | — | $11.19 | — | $0 | 2 | 2020-02-12 |
| Foundation Medicine, Inc. (FMI) Delisted | Chief Financial Officer | 49,170 | — | — | -$10.37M | 38 | 2018-07-05 |
Recent Filings
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-23 | WGS | Exer (M) | +3,576 | $0 | EDGAR |
| 2025-08-27 | WGS | Notice (144) | −39,222 | -$4.99M | EDGAR |
| 2025-08-27 | WGSWW | Sell (S) | −39,222 | -$5.00M | EDGAR |
| 2025-06-23 | WGSWW | Mixed | +12,924 | $0 | EDGAR |
| 2025-02-25 | — | Disp (D) | — | $0 | |
| 2024-11-21 | WGSWW | Mixed | −188,356 | -$3.32M | EDGAR |
| 2024-11-19 | WGS | Notice (144) | −47,000 | -$3.29M | EDGAR |
| 2024-10-17 | WGSWW | Exer (M) | +130 | $0 | EDGAR |
| 2024-06-27 | WGSWW | Grant (A) | — | $0 | EDGAR |
| 2024-05-31 | Singular Genomics Systems, Inc. (OMIC) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.